Strong Market Entry and Strategic Expansion Drive Buy Rating for Autolus

William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating on April 25.

Matt Phipps has given his Buy rating due to a combination of factors, primarily driven by the promising initial sales of Aucatzyl in the adult ALL market. The first-quarter sales of $9 million significantly exceeded expectations, indicating a strong market entry and suggesting that Autolus is effectively capturing market share from competitors like Gilead’s Tecartus.
Additionally, the expansion of authorized treatment centers is expected to enhance Aucatzyl’s market penetration, with plans to increase coverage to 90% of the target population by the end of the year. The company’s strategic initiatives, including the development of obe-cel for lupus nephritis, further bolster the growth potential. These factors collectively support a positive outlook for Autolus, justifying the Buy rating.

In another report released on April 25, Needham also maintained a Buy rating on the stock with a $10.00 price target.